CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
PH12000002657B1
(en)
*
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
RU2254340C2
(ru)
*
|
2000-03-17 |
2005-06-20 |
Киссеи Фармасьютикал Ко., Лтд. |
Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
|
EP2163555A1
(en)
|
2000-11-02 |
2010-03-17 |
Ajinomoto Co., Inc. |
New pyrazole derivatives and diabetic medicine containing them
|
JP4591781B2
(ja)
*
|
2000-11-02 |
2010-12-01 |
味の素株式会社 |
新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
|
CA2429833A1
(en)
*
|
2000-11-30 |
2002-06-06 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
CN1238363C
(zh)
|
2000-12-28 |
2006-01-25 |
橘生药品工业株式会社 |
吡喃葡糖氧基吡唑衍生物及其在药物中的应用
|
JP4141258B2
(ja)
*
|
2001-02-26 |
2008-08-27 |
キッセイ薬品工業株式会社 |
グルコピラノシルオキシピラゾール誘導体及びその医薬用途
|
ES2350084T3
(es)
*
|
2001-02-27 |
2011-01-18 |
Kissei Pharmaceutical Co., Ltd. |
Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
CN100384430C
(zh)
|
2001-04-04 |
2008-04-30 |
奥索-麦克尼尔药品公司 |
含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
|
ATE423559T1
(de)
|
2001-04-04 |
2009-03-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
|
EP1385856B1
(en)
*
|
2001-04-11 |
2006-02-22 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
EP1389621A4
(en)
|
2001-04-27 |
2005-05-11 |
Ajinomoto Kk |
N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
|
US7217697B2
(en)
|
2001-05-30 |
2007-05-15 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
|
BR0210510A
(pt)
*
|
2001-06-20 |
2005-01-11 |
Kissei Pharmaceutical |
Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo
|
WO2003011880A1
(fr)
*
|
2001-07-31 |
2003-02-13 |
Kissei Pharmaceutical Co., Ltd. |
Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
WO2003090783A1
(fr)
*
|
2002-04-26 |
2003-11-06 |
Ajinomoto Co., Inc. |
Agent preventif/remede pour diabete
|
US7956041B2
(en)
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
DE10231370B4
(de)
*
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
ES2345250T3
(es)
*
|
2002-08-08 |
2010-09-20 |
Kissei Pharmaceutical Co., Ltd. |
Derivado de pirazol en la composicion medicinal que contiene el mismo, el uso medicinal del mismo, y un intermedio para la produccion del mismo.
|
CN100351263C
(zh)
*
|
2002-08-08 |
2007-11-28 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
WO2004014930A1
(ja)
*
|
2002-08-09 |
2004-02-19 |
Taisho Pharmaceutical Co., Ltd. |
選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法
|
ZA200501549B
(en)
*
|
2002-08-23 |
2006-07-26 |
Kissei Pharmaceutical |
Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof and intermediate for the production thereof
|
JP2004137245A
(ja)
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
JP4606876B2
(ja)
*
|
2002-08-27 |
2011-01-05 |
キッセイ薬品工業株式会社 |
ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
|
WO2004031203A1
(ja)
*
|
2002-10-04 |
2004-04-15 |
Kissei Pharmaceutical Co., Ltd. |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
KR20050089156A
(ko)
*
|
2002-12-04 |
2005-09-07 |
깃세이 야쿠힌 고교 가부시키가이샤 |
고혈당증에 기인하는 질환의 예방 또는 치료제
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
CA2509835A1
(en)
*
|
2002-12-25 |
2004-07-15 |
Kissei Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
|
US7439232B2
(en)
|
2003-04-01 |
2008-10-21 |
Taisho Pharmaceutical Co., Ltd. |
Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
|
WO2004089966A1
(ja)
*
|
2003-04-01 |
2004-10-21 |
Taisho Pharmaceutical Co., Ltd. |
選択的なヘテロアリール 5-チオ-β-D-アルドヘキソピラノシドの製造法
|
US7576064B2
(en)
*
|
2003-06-20 |
2009-08-18 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, drug composition containing the same and production intermediate therefor
|
EP1660509B1
(de)
*
|
2003-08-26 |
2009-02-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
DE102004028241B4
(de)
|
2004-06-11 |
2007-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
|
JP5010918B2
(ja)
*
|
2004-07-21 |
2012-08-29 |
キッセイ薬品工業株式会社 |
肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
WO2006054629A1
(ja)
|
2004-11-18 |
2006-05-26 |
Kissei Pharmaceutical Co., Ltd. |
1-置換-3-(β-D-グリコピラノシル)含窒素ヘテロ環化合物、及びそれを含有する医薬
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
US8022192B2
(en)
|
2005-03-17 |
2011-09-20 |
Kissei Pharmaceutical Co., Ltd. |
Process for production of glucopyranosyloxypyrazole derivative
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
UY29694A1
(es)
*
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
RU2407737C2
(ru)
*
|
2005-08-31 |
2010-12-27 |
Ф.Хоффманн-Ля Рош Аг |
Производные пиразолона
|
UY30082A1
(es)
|
2006-01-11 |
2007-08-31 |
Boehringer Ingelheim Int |
Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US20080020987A1
(en)
*
|
2006-07-20 |
2008-01-24 |
Waldemar Pfrengle |
Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
|
MX2009005935A
(es)
|
2006-12-06 |
2009-06-30 |
Smithkline Beecham Corp |
Compuestos biciclicos y su uso como anti-diabeticos.
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
WO2010023594A1
(en)
*
|
2008-08-28 |
2010-03-04 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
US9006280B2
(en)
*
|
2008-11-20 |
2015-04-14 |
Teikoku Pharma Usa, Inc. |
Pyrazolone derivative formulations
|
EP2375896A4
(en)
*
|
2008-11-21 |
2012-07-18 |
Glaxosmithkline Llc |
CHEMICAL PROCESS
|
CN101445528B
(zh)
*
|
2008-12-25 |
2011-06-15 |
天津药物研究院 |
硫代葡萄糖衍生物、其制备方法和用途
|
AU2010212867B2
(en)
|
2009-02-13 |
2013-05-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
|
EA024072B1
(ru)
*
|
2009-02-13 |
2016-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
|
NZ598318A
(en)
|
2009-09-30 |
2014-02-28 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
KR101813025B1
(ko)
|
2009-09-30 |
2017-12-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실치환된 벤질벤젠 유도체의 제조방법
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
US8163704B2
(en)
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
AU2010309788A1
(en)
|
2009-10-20 |
2012-04-05 |
Novartis Ag |
Glycoside derivative and uses thereof
|
KR101426180B1
(ko)
|
2009-11-02 |
2014-07-31 |
화이자 인코포레이티드 |
디옥사-비시클로[3.2.1]옥탄-2,3,4-트리올 유도체
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
US8614195B2
(en)
|
2011-04-14 |
2013-12-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
CN103619862A
(zh)
|
2011-04-14 |
2014-03-05 |
诺瓦提斯公司 |
糖苷衍生物及其用途
|
CA2837627A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
UA113086C2
(xx)
|
2012-05-10 |
2016-12-12 |
|
Піразольні сполуки як інгібітори sglt1
|
TW201425326A
(zh)
|
2012-10-05 |
2014-07-01 |
Lilly Co Eli |
新穎脲化合物
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN105377266A
(zh)
|
2013-04-18 |
2016-03-02 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
AR098670A1
(es)
|
2013-11-08 |
2016-06-08 |
Lilly Co Eli |
Inhibidor de sglt1
|
EP3862003B1
(en)
|
2013-12-17 |
2023-10-25 |
Boehringer Ingelheim Vetmedica GmbH |
An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals
|
CN105960242A
(zh)
|
2014-01-23 |
2016-09-21 |
勃林格殷格翰动物保健有限公司 |
犬科动物中代谢紊乱的治疗
|
CA2943704C
(en)
|
2014-04-01 |
2023-03-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
FI3197429T3
(fi)
|
2014-09-25 |
2024-06-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Yhdistelmähoito sglt2:n estäjillä ja dopamiiniagonisteilla aineenvaihduntahäiriöiden ehkäisemiseksi hevoseläimissä
|
CN104478967A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104447905A
(zh)
*
|
2015-01-14 |
2015-03-25 |
佛山市赛维斯医药科技有限公司 |
一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104447907A
(zh)
*
|
2015-01-14 |
2015-03-25 |
佛山市赛维斯医药科技有限公司 |
含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478969A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478956A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478962A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类卤代苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497073A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
含丙烯腈和烷氧苯基o-葡萄糖苷结构的衍生物和用途
|
CN104497074A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含丙烯腈基和硝基苯o-葡萄糖苷结构化合物及用途
|
CN104478960A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含丙烯腈基和三氟甲苯基o-葡萄糖苷结构化合物和用途
|
CN104497072A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
含丙烯腈和卤代苯o-葡萄糖苷结构衍生物、其制备方法和用途
|
AU2017344882A1
(en)
|
2016-10-19 |
2019-03-28 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
|
JP2021520394A
(ja)
|
2018-04-17 |
2021-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、処置方法及びその使用
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN114727624A
(zh)
|
2019-11-28 |
2022-07-08 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂在非人哺乳动物的停奶中的用途
|
MX2022010090A
(es)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
|
CN117715640A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
EP4376830A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
TW202412756A
(zh)
|
2022-05-25 |
2024-04-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含sglt-2抑制劑之水性醫藥組合物
|